Gilead Sciences Reports Strong Q3 2026 Results Driven by HIV and Oncology Growth
Gilead Sciences (GILD) reported robust third-quarter 2026 financial results, highlighted by $8.2 billion in base business product sales—a 16% year-over-year increase marking its strongest growth in over a decade. The HIV franchise remains a primary driver, with revenue rising 18% to $6.2 billion, fueled by Biktarvy's record 53% U.S. market share and significant gains in Descovy sales. Oncology performance also showed momentum, with Trodelvy reaching an annual run rate of approximately $2 billion and Livdelzi seeing a 93% surge in sales. However, the company faced headwinds in its Cell Therapy segment, which declined 18% due to competitive pressures, and Veklury sales dropped significantly as COVID-19 hospitalizations waned. Looking ahead, Gilead raised its full-year 2026 revenue guidance to a range of $31 billion to $31.3 billion. Despite current strength, management cautioned that federal pricing mandates are expected to impact Biktarvy revenue by approximately $1.5 billion starting in 2028.
Tickers: $GILD
Topics: EPS HIV Treatment Oncology Product Sales Revenue Growth